X0206 3 2018-07-18 0 0001434418 CONSTELLATION PHARMACEUTICALS INC CNST 0001347769 COLUMN GROUP L P 1700 OWENS STREET, SUITE 500 SAN FRANCISCO CA 94158 0 0 1 0 0001614627 COLUMN GROUP GP, LP 1700 OWENS STREET, SUITE 500 SAN FRANCISCO CA 94158 0 0 1 0 0001707230 PONOI CAPITAL, LP 1700 OWENS STREET, SUITE 500 SAN FRANCISCO CA 94158 0 0 1 0 0001720702 Ponoi Management, LLC 1700 OWENS STREET, SUITE 500 SAN FRANCISCO CA 94158 0 0 1 0 0001732601 Ponoi Capital II, LP 1700 OWENS STREET, SUITE 500 SAN FRANCISCO CA Ponoi Capi 0 0 1 0 0001746488 Ponoi II Management, LLC 1700 OWENS STREET, SUITE 500 SAN FRANCISCO CA 94158 0 0 1 0 0001182464 GOEDDEL DAVID V 1700 OWENS STREET, SUITE 500 SAN FRANCISCO CA 94158 0 0 1 0 0001614186 Kutzkey Tim 1700 OWENS STREET, SUITE 500 SAN FRANCISCO CA 94158 0 0 1 0 Common Stock 11051 D Series A Preferred Stock Common Stock 999180 D Series B Preferred Stock Common Stock 756955 D Series D Preferred Stock Common Stock 88124 D Series E Preferred Stock Common Stock 415244 D Series E Preferred Stock Common Stock 51905 I See footnote Series E-1 Preferred Stock Common Stock 590689 D Series F Preferred Stock Common Stock 1816696 D Series F Preferred Stock Common Stock 27250 I See footnote Warrant (right to buy) 1.55 2021-05-24 Common Stock 30107 D The securities are directly held by Ponoi Capital, LP, and indirectly held by Ponoi Management, LLC, the general partner of Ponoi Capital, LP. The managing partners of Ponoi Management, LLC are David Goeddel, Peter Svennilson, and Tim Kutzkey. The managing partners of Ponoi Management, LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. The Series A Preferred Stock is convertible into Common Stock on a 11.009-for-one basis into the number of shares of Common Stock shown in Column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. The securities are directly held by The Column Group, LP, and indirectly held by The Column Group GP, LP, the general partner of The Column Group, LP. The managing partners of The Column Group GP, LP are David Goeddel and Peter Svennilson. The managing partners of The Column Group GP, LP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. The Series B Preferred Stock is convertible into Common Stock on a 11.009-for-one basis into the number of shares of Common Stock shown in Column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. The Series D Preferred Stock is convertible into Common Stock on a 11.009-for-one basis into the number of shares of Common Stock shown in Column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. The Series E Preferred Stock is convertible into Common Stock on a 8.56256-for-one basis into the number of shares of Common Stock shown in Column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. The securities are held directly by The David V. and Alena Z. Goeddel 2004 Trust. The Series E-1 Preferred Stock is convertible into Common Stock on a 11.009-for-one basis into the number of shares of Common Stock shown in Column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Consists of an aggregate of 295,347 shares of Common Stock issuable upon the conversion of shares of Series E-1 Preferred Stock held directly by The Column Group, LP and 295,342 shares of Common Stock issuable upon the conversion of shares of Series E-1 Preferred Stock held directly by Ponoi Capital, LP. The Series F Preferred Stock is convertible into Common Stock on a 11.009-for-one basis into the number of shares of Common Stock shown in Column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Consists of an aggregate of 908,349 shares of Common Stock issuable upon the conversion of shares of Series F Preferred Stock held directly by Ponoi Capital, LP and 908,347 shares of Common Stock issuable upon the conversion of shares of Series F Preferred Stock held directly by Ponoi Capital II, LP. The securities are directly held by Ponoi Capital II, LP, and indirectly held by Ponoi II Management, LLC, the general partner of Ponoi Capital II, LP. The managing partners of Ponoi II Management, LLC are David Goeddel, Peter Svennilson, and Tim Kutzkey. The managing partners of Ponoi II Management, LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. The warrant is fully exercisable. Exhibit Index: 24.1 Power of Attorney Exhibit Index: 24.2 Power of Attorney Exhibit Index: 24.3 Power of Attorney Exhibit Index: 24.4 Power of Attorney Exhibit Index: 24.5 Power of Attorney /s/ Jennifer J. Carlson, Attorney-in-Fact 2018-07-18